STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Future Oncol
; 19(9): 631-642, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-37083373
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Leukemia, Myelomonocytic, Chronic
/
Leukemia, Myeloid, Acute
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom